Positive results were observed across all subgroups Study meets several key secondary endpoints with statistical significance SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. – United Therapeutics Corporation, a public benefit… Read More
Vabysmo now covered across all three approved indications in the province, providing patients with a single, comprehensively funded solution MISSISSAUGA, ON- Hoffmann-La Roche Limited (Roche Canada) is pleased to announce… Read More
Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the potential for… Read More
At 12 months, 2/3rds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission after their treatment with EP-104GI All Cohorts followed to 9 months have maintained… Read More
Health Canada has approved ELAHERE® , the first novel therapy to demonstrate statistically significant and clinically meaningful improvements in overall survival (OS) compared to chemotherapy alone for patients with platinum-resistant… Read More
